Roivant plans to initiate Phase 2 clinical trial in 2019 Agreement includes option to in-license additional anti-Gr(+) programs Roivant Sciences and iNtRON Biotechnology today announced that they have entered into a global licensing agreement for SAL200, a novel investigational biologic for the treatment of...
iNtRON Biotechnology has announced that N-Rephasin BAL200 for the treatment of anthrax infection has been received Orphan Drug Designation (ODD) from the US Food and Drug Administration (US FDA). Orphan Drug Designation is a program of FDA to support for the new drug development of rare...
On June 22, 2018, The 6th Korea Bacteriophage Research Society meeting was held at the iNtRON Bio’s conference room. 40 prominent bacteriophage researchers and related industry specialists have participated in the meeting, and Professor Yong of Yonsei University, Professor Bae of Seoul National University, and Research...
To Focus on Investor Relations and Global Business Development As iNtRON Biotechnology (hereafter “iNtRON”) has grown up steadily, iNtRON has opened a new Seoul Office in the center of Seoul with great accessibility to focus on global business and investor relations. iNtRON is developing novel...
“Nightmare bacteria” with the power to resist most antibiotics are popping up across the U.S., but new, aggressive policies can help stop them from spreading, federal health officials said Tuesday. A new program for testing suspect bacteria turned up unusual antibiotic-resistance genes 221 times in...
In January 2018, The Catholic University of Korea’s Division of Infectious Disease released a paper on the subject of seriousness of multidrug-resistant organisms (MDROs) and suggested control methods to prevent bacterial epidemic disease occurrence. Seriousness of MDROs MDROs including Carbapenem resistance bacteria or well known...